**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 36-year-old man developed coronavirus disease-19 (COVID-19) during treatment with azathioprine, infliximab and mesalazine for ulcerative colitis.

The man, who had ulcerative colitis and a flare up since 4 months, was receiving azathioprine 100 mg/day, oral mesalazine and oral infliximab 5 mg/kg/8 weeks \[*not all routes and dosages stated*\]. The most recent dose was taken on 28 Feb 2020. On 27 Mar 2020, he was admitted because of dyspnoea, irritating cough and fever. His PCR for COVID-19 was positive and chest X-ray showed bilateral subpleural infiltrates \[*durations of treatments to reaction onset not stated*\]. He was having these symptoms from 9 days. He had a baseline partial pressure of oxygen of 68mm Hg and was given 3 litres of nasal cannulae. His D-dimer was 0.86 μg/ml, CRP was 18.8 mg/dL, leukocytes were 16 000 /μL and lymphocytes were 1100 /μL. He received an off-label treatment with hydroxychloroquine and azithromycin. Due to the appearance of pulmonary infiltrate and to avoid a flare up of his disease, he was given 5 cartridges of Adacolumn.

The man was discharged on the 5^th^ day with significant improvement. At that time, his CRP was 3.4 mg/dL, lymphocytes were 2100 /μL, leukocytes were 4900 /μL and he did not need oxygen.
